TABLE 5.
International series of long-term survivors after treatment for pancreatic adenocarcinoma
| Series | No. of patients |
PD (%) |
Stages included |
Adjuvant treatment (%) |
R0 (%) |
R1/R2 (%) |
N1 (%) |
Vascular resection (%) |
Median OS (Mo) |
Actual 5-year survivors, n (rate %) |
|---|---|---|---|---|---|---|---|---|---|---|
| MDACC (current study) | 329 | 92 | PR, BR | 91 | 84 | 16/0 | 48 | 33 | 24 | 88 (27) |
| Mayo Clinic13 | 357 | 100 | PR, LA, M | 77 | 77 | 18/5 | 49 | 13 | 17 | 62 (17) |
| Johns Hopkins12 | 564 | 100 | NR | NR | NR | NR | NR | NR | NR | 96 (17) |
| Memorial Sloan-Kettering Cancer Center9 | 618 | 85 | PR, M | 21 | 73 | 27/0 | NR | 0 | NR | 75 (12) |
| University of Indiana11 | 226 | 90 | PR, LA | 34 | 70 | 28/2 | 56 | 6 | 13 | 9 (4) |
| Seoul National University, Korea10 | 123 | 81 | PR, LA, M | 49 | 76 | 24a | 54 | 14 | 15 | 11 (9) |
| Mount Sinai Hospital, Toronto8 | 123 | 91 | PR, LA | 21 | NR | 15b | 43 | 10 | 14 | 18 (15) |
PD pancreaticoduodenectomy, PR potentially resectable, BR borderline resectable, LA locally advanced, M metastatic, NR not reported, OS overall survival, N1 positive regional lymphadenopathy
a
No distinction made between R1 and R2 resections
b
No distinction made between R1 and R2 resections; number of R0 resections not stated